Baldwin Wealth Partners’s Editas Medicine EDIT Stock Holding History

Baldwin Wealth Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8	Closed	-$37	–	1111
2024 Q2	$37	Buy	+8	New	+$45	﹤0.01%	782
2022 Q4	–	Sell	-321	Closed	-$4K	–	792
2022 Q3	$4K	Hold	321	–	–	﹤0.01%	576
2022 Q2	$4K	Hold	321	–	–	﹤0.01%	604
2022 Q1	$6K	Buy	321 +180	+128%	+$3.35K	﹤0.01%	572
2021 Q4	$4K	Hold	141	–	–	﹤0.01%	572
2021 Q3	$6K	Buy	141 +21	+18%	+$1.15K	﹤0.01%	555
2021 Q2	$7K	Hold	120	–	–	﹤0.01%	556
2021 Q1	$5K	Hold	120	–	–	﹤0.01%	556
2020 Q4	$8K	Hold	120	–	–	﹤0.01%	467
2020 Q3	$3K	Hold	120	–	–	﹤0.01%	493
2020 Q2	$4K	Hold	120	–	–	﹤0.01%	477
2020 Q1	$2K	Hold	120	–	–	﹤0.01%	513
2019 Q4	$4K	Sell	120 -50	-29%	-$1.25K	﹤0.01%	489
2019 Q3	$4K	Hold	170	–	–	﹤0.01%	481
2019 Q2	$4K	Hold	170	–	–	﹤0.01%	476
2019 Q1	$4K	Hold	170	–	–	﹤0.01%	477
2018 Q4	$4K	Buy	+170	New	+$4.63K	﹤0.01%	472

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baldwin Wealth Partners's EDIT Position: Q3 2024 in Review

Baldwin Wealth Partners sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 8 shares — an estimated $37 sold.

Baldwin Wealth Partners first reported a position in EDIT in Q4 2018 and held it in 17 quarters. The position peaked at $8K in Q4 2020. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

Baldwin Wealth Partners reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 8 Editas Medicine shares in Q3 2024, an estimated $37.
Baldwin Wealth Partners first reported a position in Editas Medicine in Q4 2018 and held it in 17 quarters.
Baldwin Wealth Partners's Editas Medicine position peaked at $8K in Q4 2020.
229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Baldwin Wealth Partners's 13F filing for Q3 2024, filed 16 Oct 2024.